11 recruiting, 1 no longer available. 8 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 1 | 6 | Recruiting 6 |
| Phase 3 | 3 | Recruiting 3 |
Follow Ifinatamab Deruxtecan: new trials by email Literature Review of Ifinatamab Deruxtecan trials Research Report on Ifinatamab Deruxtecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 134 | 2026-07-06 | 2026-10-30 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-10-02 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-10-27 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-10-07 |
| A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 96 | 2025-05-13 | 2026-10-27 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Ifinatamab deruxtecan, Docetaxel, Prednisone - Prostate Cancer, Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1440 | 2025-05-13 | 2026-10-30 |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Ifinatamab deruxtecan, Docetaxel, Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Daiichi Sankyo | 510 | 2025-03-27 | 2026-10-26 |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) Ifinatamab deruxtecan, Atezolizumab, Carboplatin - Extensive Stage-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 123 | 2024-07-22 | 2026-10-01 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) Ifinatamab deruxtecan - Recurrent or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 680 | 2024-04-10 | 2026-10-26 |
| Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer Ifinatamab Deruxtecan - SCLC, Extensive-stage Small Cell Lung Cancer | No longer available | Daiichi Sankyo | 2026-10-06 |
Esophageal Squamous Cell Carcinoma (3) · Small Cell Lung Carcinoma (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Merck Sharp & Dohme LLC (7) · Daiichi Sankyo (5)
United States (12) · Spain (9) · France (8) · Germany (8) · Italy (8) · Chile (7) · Japan (7) · Poland (7) · South Korea (7) · Taiwan (7) · Turkey (Türkiye) (7) · Brazil (6) · China (6) · Netherlands (6) · Australia (5)
2023 (4), 2025 (1)